Biocon Toekomstige groei
Future criteriumcontroles 4/6
Biocon zal naar verwachting groeien in winst en omzet met respectievelijk 47.6% en 13.1% per jaar. De winst per aandeel zal naar verwachting groeien met 44.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 5.7% zijn.
Belangrijke informatie
47.6%
Groei van de winst
44.49%
Groei van de winst per aandeel
| Biotechs winstgroei | 35.2% |
| Inkomstengroei | 13.1% |
| Toekomstig rendement op eigen vermogen | 5.68% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 21 May 2026 |
Recente toekomstige groei-updates
Analyseartikel • Aug 10
Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models
NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...Analyseartikel • Jun 19
Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next
Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...Recent updates
Analyseartikel • May 21
Biocon's (NSE:BIOCON) Weak Earnings May Only Reveal A Part Of The Whole Picture
The subdued market reaction suggests that Biocon Limited's ( NSE:BIOCON ) recent earnings didn't contain any surprises...
Narratiefupdate • May 03
BIOCON: Leadership Changes And Biosimilars Expansion Will Support Future Upside
Biocon's analyst price target has been trimmed slightly to about ₹416 from roughly ₹421 as analysts factor in a marginally higher discount rate, slightly softer revenue growth and profit margin assumptions, partly balanced by a modestly higher future P/E multiple. Analyst Commentary Recent Street research around comparable life sciences names points to a cautious tone on execution risk, revenue trajectory and the willingness of the market to pay up for growth after guidance disappointments.
Narratiefupdate • Apr 19
BIOCON: Higher Profitability Assumptions Will Support U.S. Biosimilars And GLP-1 Entry
Narrative Update on Biocon Analysts have adjusted their price target on Biocon to ₹544, up from ₹465. This reflects updated assumptions around a higher fair value estimate, revised profit margin expectations, and a slightly different discount rate and forward P/E framework.Narratiefupdate • Apr 05
BIOCON: Leadership Refresh And Biosimilars Integration Will Support Future Upside
Analysts have trimmed Biocon's fair value estimate slightly to ₹420.74 from ₹421.60, reflecting updated assumptions around the discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts are treating the trimmed fair value estimate as a fine tuning of expectations rather than a major reset, with views split between what could support upside and what might cap near term returns.
Narratiefupdate • Mar 21
BIOCON: Limited P/E Expansion Will Constrain Returns Despite New Metabolic Drug Approvals
Analysts have trimmed their Biocon price target slightly to about ₹295.70 from roughly ₹297.40, reflecting a modest recalibration of fair value, discount rate and long term assumptions for revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts trimming Biocon's fair value signal a more careful stance on what they are willing to pay for the shares today, given reassessed views on growth, profitability and valuation multiples.Narratiefupdate • Mar 07
BIOCON: Limited Multiple Expansion Will Constrain Returns Despite New GLP 1 Approvals
Narrative update Analysts have trimmed their Biocon price target slightly to about ₹297 from roughly ₹298, reflecting updated assumptions on discount rate, revenue growth, profit margins and future P/E multiples after recent sector research signalled a more cautious stance on multiple expansion. Analyst Commentary Bearish analysts looking at global life sciences peers have trimmed price targets after recent earnings misses and cautious forward commentary, and those moves are informing how some investors think about Biocon's risk and valuation setup.Narratiefupdate • Feb 21
BIOCON: Execution And Multiple Compression Risks Will Restrain Future Share Returns
Analysts have inched up their Biocon fair value estimate to about ₹298 per share from roughly ₹295, reflecting slightly lower discount rate assumptions, modestly softer revenue growth expectations, a somewhat stronger profit margin outlook, and a marginally reduced future P/E multiple. Analyst Commentary While the fair value adjustment for Biocon is modest, some bearish analysts are still flagging risks that could cap upside in the near term.Narratiefupdate • Feb 07
BIOCON: Equity Dilution And Biosimilars Review Will Pressure Future Returns
Analysts have slightly reduced their Biocon fair value estimate to ₹295.12 from ₹296.78, citing updated assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News Biocon completed a follow on equity offering of equity shares worth ₹41.5b, issuing 112,664,585 common shares at ₹368.35 each under a Regulation S structure with a subsequent direct listing (company filing).Narratiefupdate • Jan 23
BIOCON: Biosimilars Reorganisation And GLP 1 Expansion Will Drive Future Upside
Analysts have nudged their fair value estimate for Biocon higher from ₹412.05 to ₹421.60, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E multiples in their valuation work. What's in the News Biocon completed a follow on equity offering of ₹41.5b, issuing 112,664,585 equity shares at ₹368.35 per share under Regulation S, followed by a subsequent direct listing (Key Developments).Narratiefupdate • Jan 09
BIOCON: Planned Capital Raise Will Likely Weigh On Future Shareholder Returns
Analysts have lifted their price target on Biocon from ₹290.00 to about ₹296.78, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and forward P/E inputs in their models. What's in the News Shareholders approved amendments to Biocon's Articles of Association at the AGM held on December 31, 2025, signaling changes to the company's governing documents (Key Developments).Narratiefupdate • Dec 26
BIOCON: Future Equity Issuance Will Likely Pressure Shareholder Returns
Analysts have maintained their fair value estimate for Biocon at ₹290.00 per share, with only minor model adjustments to discount rate, revenue growth, and profit margin assumptions. These changes have resulted in no alteration to their overall price target, as they continue to view the company’s long term earnings profile as broadly intact.Analyseartikel • Dec 25
Calculating The Fair Value Of Biocon Limited (NSE:BIOCON)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Biocon fair value estimate is ₹364 With ₹398 share price...Narratiefupdate • Dec 12
BIOCON: Future Share Dilution Risk Will Likely Pressure Returns
Analysts have raised their price target on Biocon from ₹277.50 to ₹290.00, reflecting higher anticipated revenue growth, improved profit margins, and a modestly re-rated future P E multiple despite a slightly higher discount rate. What's in the News Biocon is exploring strategic options for its biosimilars arm Biocon Biologics Limited, including a potential merger with the parent company in place of an IPO, with Morgan Stanley advising on value creation alternatives (Key Developments).Analyseartikel • Dec 07
Investors Don't See Light At End Of Biocon Limited's (NSE:BIOCON) Tunnel
You may think that with a price-to-sales (or "P/S") ratio of 3.2x Biocon Limited ( NSE:BIOCON ) is a stock worth...Narratiefupdate • Nov 27
BIOCON: Global Expansion And Business Restructuring Are Expected To Balance Opportunities And Risks
Analysts have raised their price target for Biocon from ₹395.65 to ₹412.05. This change reflects updated expectations around key valuation inputs and profitability metrics.Analyseartikel • Nov 19
Weak Statutory Earnings May Not Tell The Whole Story For Biocon (NSE:BIOCON)
The market rallied behind Biocon Limited's ( NSE:BIOCON ) stock, leading do a rise in the share price after its recent...Narratiefupdate • Nov 13
BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance
Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.Narratiefupdate • Oct 05
Biosimilars Demand Will Unlock Global Market Opportunities
Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.Analyseartikel • Sep 22
Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 56% Above Its Share Price
Key Insights The projected fair value for Biocon is ₹577 based on 2 Stage Free Cash Flow to Equity Biocon's ₹369 share...Analyseartikel • Aug 10
Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models
NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...Analyseartikel • Aug 04
Pinning Down Biocon Limited's (NSE:BIOCON) P/E Is Difficult Right Now
Biocon Limited's ( NSE:BIOCON ) price-to-earnings (or "P/E") ratio of 50.5x might make it look like a strong sell right...Analyseartikel • Jun 19
Biocon Limited Just Recorded A 16% EPS Beat: Here's What Analysts Are Forecasting Next
Shareholders might have noticed that Biocon Limited ( NSE:BIOCON ) filed its yearly result this time last week. The...Analyseartikel • Jun 18
Biocon (NSE:BIOCON) Will Pay A Dividend Of ₹0.50
The board of Biocon Limited ( NSE:BIOCON ) has announced that it will pay a dividend on the 5th of September, with...
Nieuw narratief • Dec 12
Tactical Biosimilars Expansion And Viatris Integration Will Propel Revenue Growth And Boost Profitability
Strategic cost improvements and production efficiencies are set to enhance margins and profitability in the generics segment.Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2029 | 249,133 | 21,939 | 24,827 | 47,141 | 6 |
| 3/31/2028 | 228,628 | 19,945 | 27,427 | 41,522 | 18 |
| 3/31/2027 | 200,534 | 13,692 | 22,775 | 38,096 | 18 |
| 3/31/2026 | 169,270 | 3,856 | 823 | 19,940 | N/A |
| 12/31/2025 | 168,274 | 6,042 | N/A | N/A | N/A |
| 9/30/2025 | 164,758 | 4,855 | 17,973 | 41,592 | N/A |
| 6/30/2025 | 157,707 | 3,850 | N/A | N/A | N/A |
| 3/31/2025 | 152,617 | 10,133 | 17,179 | 40,612 | N/A |
| 12/31/2024 | 147,618 | 8,043 | N/A | N/A | N/A |
| 9/30/2024 | 148,941 | 14,392 | 21,045 | 40,368 | N/A |
| 6/30/2024 | 147,660 | 15,808 | N/A | N/A | N/A |
| 3/31/2024 | 147,557 | 10,225 | 10,223 | 29,539 | N/A |
| 12/31/2023 | 146,125 | 12,002 | N/A | N/A | N/A |
| 9/30/2023 | 135,999 | 4,984 | -6,241 | 11,717 | N/A |
| 6/30/2023 | 124,573 | 4,197 | N/A | N/A | N/A |
| 3/31/2023 | 111,742 | 4,627 | 1,262 | 18,525 | N/A |
| 12/31/2022 | 98,091 | 3,881 | N/A | N/A | N/A |
| 9/30/2022 | 90,422 | 6,170 | -6,836 | 11,543 | N/A |
| 6/30/2022 | 85,629 | 7,084 | N/A | N/A | N/A |
| 3/31/2022 | 81,840 | 6,484 | -7,482 | 11,766 | N/A |
| 12/31/2021 | 75,800 | 6,727 | N/A | N/A | N/A |
| 9/30/2021 | 72,632 | 6,542 | -6,366 | 12,763 | N/A |
| 6/30/2021 | 71,726 | 6,852 | N/A | N/A | N/A |
| 3/31/2021 | 71,431 | 7,405 | -5,866 | 11,597 | N/A |
| 12/31/2020 | 68,913 | 5,996 | N/A | N/A | N/A |
| 9/30/2020 | 67,571 | 6,362 | -6,576 | 10,484 | N/A |
| 6/30/2020 | 65,796 | 6,870 | N/A | N/A | N/A |
| 3/31/2020 | 63,005 | 7,771 | -5,534 | 12,831 | N/A |
| 12/31/2019 | 63,150 | 8,385 | N/A | N/A | N/A |
| 9/30/2019 | 61,077 | 8,529 | N/A | 14,573 | N/A |
| 6/30/2019 | 58,565 | 9,919 | N/A | N/A | N/A |
| 3/31/2019 | 55,144 | 9,053 | N/A | 11,546 | N/A |
| 12/31/2018 | 51,551 | 8,220 | N/A | N/A | N/A |
| 9/30/2018 | 46,722 | 6,967 | N/A | N/A | N/A |
| 6/30/2018 | 43,198 | 4,108 | N/A | N/A | N/A |
| 3/31/2018 | 41,234 | 3,724 | N/A | 6,621 | N/A |
| 12/31/2017 | 38,792 | 3,695 | N/A | N/A | N/A |
| 9/30/2017 | 38,589 | 4,489 | N/A | N/A | N/A |
| 6/30/2017 | 38,361 | 5,268 | N/A | N/A | N/A |
| 3/31/2017 | 38,911 | 6,121 | N/A | 6,400 | N/A |
| 12/31/2016 | 40,487 | 11,633 | N/A | N/A | N/A |
| 9/30/2016 | 38,110 | 10,961 | N/A | N/A | N/A |
| 6/30/2016 | 36,539 | 9,388 | N/A | N/A | N/A |
| 3/31/2016 | 33,474 | 5,504 | N/A | 3,706 | N/A |
| 12/31/2015 | 32,997 | 7,367 | N/A | N/A | N/A |
| 9/30/2015 | 32,325 | 7,247 | N/A | N/A | N/A |
| 6/30/2015 | 31,528 | 5,207 | N/A | N/A | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei BIOCON ( 47.6% per jaar) ligt boven de spaarquote ( 6.9% ).
Winst versus markt: De winst van BIOCON ( 47.6% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 16.3% per jaar).
Hoge groeiwinsten: De winst van BIOCON zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van BIOCON ( 13.1% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.8% per jaar).
Hoge groei-inkomsten: De omzet van BIOCON ( 13.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen BIOCON zal naar verwachting over 3 jaar laag zijn ( 5.7 %).
Ontdek groeibedrijven
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 19:04 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Biocon Limited wordt gevolgd door 39 analisten. 18 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Meeta Shetty | Asian Markets Securities Private Limited |
| Harith Ahamed | Avendus Spark |